Figure 4
Mesenchymal and Immunoreactive MRs correlate with tumor stroma and patient survival.
(A) Heatmap of Mesenchymal and Immunoreactive MRs expression and ssGSEA scores for four molecular subtypes of TCGA samples. Binary scores were shown to indicate whether a tumor sample activated Mesenchymal or Immunoreactive MRs. Red, activated; black, not activated. (B) Mesenchymal and Immunoreactive MRs scores in microdissected tumor stroma (5 samples in GSE9890 and 31 samples in GSE40595) versus epithelial tissues (5 samples in GSE9890 and 32 samples in GSE40595). (C) Mesenchymal and Immunoreactive MRs scores in PDX versus matched primary tumors (9 samples). (D) Mesenchymal and Immunoreactive MRs scores in tumor metastasis versus primary tumors (9 paired samples). (E) Mesenchymal and Immunoreactive MRs scores in tumors treated with chemotherapy (34 samples) versus non-treated tumors (35 samples). (F) Kaplan Meier curves for three prognostic groups of TCGA samples classified by Mesenchymal and Immunoreactive MRs signatures. G. Kaplan Meier curves for meta-analysis of 749 HGS-OvCa expression profiles across five cohorts. H. Kaplan Meier curves for ‘immu + mese−’ and ‘immu + mese+’ patients.
